Literature DB >> 15357900

Prion diseases and the spleen.

Nathalie Daude1.   

Abstract

Transmissible spongiform encephalopathies are fatal neurodegenerative disorders that include Creutzfeldt-Jakob disease in humans, bovine spongiform encephalopathy and scrapie in sheep and goats. Transmissible spongiform encephalopathies are thought by some to result from changes in the conformation of a membrane glycoprotein called PrPC (prion protein) into a pathogenic form, PrPSc, which constitutes the major component of an unprecedented type of infectious particle supposedly devoid of nucleic acid. Although there is no primary immunological response to the infectious agent, several lines of evidence indicate an involvement of the lymphoreticular system in the development of prion diseases. Studies in rodents have shown that after peripheral infection, uptake of the scrapie agent is followed by an initial phase of replication in the lymphoreticular system, particularly the spleen and lymph nodes. Moreover, infectivity titers in lymphoreticular organs reach a maximum relatively quickly, well before those in the brain, and then maintain a plateau for the remainder of the disease progression. The presence of PrPSc in peripheral lymphoid organs of all cases of variant Creutzfeldt-Jakob disease strongly underscores the importance of the lymphoreticular system. Thus, a better understanding of the cells participating in PrPSc replication and dissemination into the central nervous system is of particular interest. This review will therefore discuss the present knowledge of the role of the spleen in transmissible spongiform encephalopathies as well as the participation of the different spleen cell types in the disease process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15357900     DOI: 10.1089/vim.2004.17.334

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  6 in total

1.  PrP(Sc)-specific antibodies do not induce prion disease or misfolding of PrP(C) in highly susceptible Tga20 mice.

Authors:  Pekka Määttänen; Ryan Taschuk; Li Ross; Kristen Marciniuk; Lisa Bertram; Andrew Potter; Neil R Cashman; Scott Napper
Journal:  Prion       Date:  2013-10-08       Impact factor: 3.931

Review 2.  Immunotherapy in prion disease.

Authors:  Yvonne Roettger; Yansheng Du; Michael Bacher; Inga Zerr; Richard Dodel; Jan-Philipp Bach
Journal:  Nat Rev Neurol       Date:  2012-12-18       Impact factor: 42.937

3.  Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.

Authors:  Tehila Mayer-Sonnenfeld; Dana Avrahami; Yael Friedman-Levi; Ruth Gabizon
Journal:  Cell Mol Neurobiol       Date:  2008-03-19       Impact factor: 5.046

4.  Fatal neurological disease in scrapie-infected mice induced for experimental autoimmune encephalomyelitis.

Authors:  Yael Friedman-Levi; Haim Ovadia; Romana Hoftberger; Ofira Einstein; Oded Abramsky; Herbert Budka; Ruth Gabizon
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

5.  Targeting of prion-infected lymphoid cells to the central nervous system accelerates prion infection.

Authors:  Yael Friedman-Levi; Romana Hoftberger; Herbert Budka; Tehila Mayer-Sonnenfeld; Oded Abramsky; Haim Ovadia; Ruth Gabizon
Journal:  J Neuroinflammation       Date:  2012-03-21       Impact factor: 8.322

6.  PRNP promoter polymorphisms are associated with BSE susceptibility in Swiss and German cattle.

Authors:  Bianca Haase; Marcus G Doherr; Torsten Seuberlich; Cord Drögemüller; Gaudenz Dolf; Petra Nicken; Katrin Schiebel; Ute Ziegler; Martin H Groschup; Andreas Zurbriggen; Tosso Leeb
Journal:  BMC Genet       Date:  2007-04-16       Impact factor: 2.797

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.